Results 111 to 120 of about 28,581 (233)

MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells

Cell Death Discovery
The oncogenic MUC1-C transmembrane protein is a critical effector of the cancer stem cell (CSC) state. Addiction to MUC1-C for self-renewal in the progression of human cancers has emphasized the need for development of anti-MUC1-C agents.
Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Naoki Haratake, Ayako Nakashoji, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Takeo Kosaka, Mototsugu Oya, Donald W. Kufe   +10 more
doaj   +1 more source

Regulation of MUC1-specific immunity by CD4+ T cells [PDF]

, 2005
MUC1 is a large glycoprotein that is expressed on ductal epithelial cells and also the majority of epithelial adenocarcinomas. Dysregulated expression of aberrantly glycoslyated MUC1 in carcinomas allows tumor-specific recognition of MUC1-derived ...
Turner, Michael Stuart
core  

Muc1 bioactivation contributes to lung fibrosis [PDF]

, 2019
INTRODUCCIÓN La fibrosis pulmonar idiopática (FPI) es una forma específica de neumonía intersticial fibrosante, progresiva, crónica y de causa desconocida.
Ballester Llobell, Beatriz
core  

Establishment of primary cell cultures from canine mammary gland malignant tumours: a preliminary study

Journal of Veterinary Research
Canine mammary gland cancer (CMGC) is the most common neoplastic condition in bitches and is often fatal. There are limited treatment options for CMGC. Primary cell cultures from mammary tumours are promising preclinical in vitro models in which to study
Petrouškova Patŕicia, Hudáková Nikola, Almášiová Viera, Valenčáková Alexandra, Horňáková L’ubica, Huniadi Mykhailo, Čížková Daša   +6 more
doaj   +1 more source

MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer

Biomedicines
Patients with pancreatic neuroendocrine tumors (pNETs) have limited access to effective targeted agents and invariably succumb to progressive disease. MUC1-C is a druggable oncogenic protein linked to driving pan-cancers. There is no known involvement of
Hiroki Ozawa, Naoki Haratake, Ayako Nakashoji, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Keisuke Shigeta, Atsushi Fushimi, Kazumasa Fukuda, Yohei Masugi, Ryo Yamaguchi, Minoru Kitago, Hirofumi Kawakubo, Yuko Kitagawa, Donald Kufe   +14 more
doaj   +1 more source

MUC1.CT directly interacts with transcriptional repressor ZEB1.

, 2013
A) Co-immunoprecipitation (Co-IP) was utilized to evaluate the interaction of the MUC1.CT and ZEB1 in S2.013.Neo and S2.013.MUC1 cells. Cell lysates were immunoprecipitated with an antibody against the MUC1.CT, and the subsequent western was blotted ...
Xiang Liu (119470), Michael A. Hollingsworth (179339), Michelle E. Lewallen (470775), Jennifer M. Bailey (470774), Prakash Radhakrishnan (470776), William Tapprich (470777), Fang Yu (156838), Ashley M. Mohr (470773)   +7 more
core   +1 more source

Development of New Models of Oral Mucosa to Investigate the Impact of the Structure of Transmembrane Mucin-1 on the Mucosal Pellicle Formation and Its Physicochemical Properties

Biomedicines
The mucosal pellicle (MP) is a biological film protecting the oral mucosa. It is composed of bounded salivary proteins and transmembrane mucin MUC1 expressed by oral epithelial cells.
Clément Nivet, Irma Custovic, Laure Avoscan, Floris J. Bikker, Aline Bonnotte, Eric Bourillot, Loïc Briand, Hélène Brignot, Jean-Marie Heydel, Noémie Herrmann, Mélanie Lelièvre, Eric Lesniewska, Fabrice Neiers, Olivier Piétrement, Mathieu Schwartz, Christine Belloir, Francis Canon   +16 more
doaj   +1 more source

Exposure to Abnormal Self Antigens During Non-Malignant Inflammatory Events Provides Immunological Defense Against Tumors [PDF]

, 2013
Cancer immunosurveillance is the body’s sentinel mechanism of recognizing and eliminating malignancy. Specifically, the immune system can mount a response against cancer through the recognition of tumor associated antigens (TAA). While studying two TAAs,
Iheagwara, Uzoma
core  

Abstract 3330: MUC1* targeting CAR T

, 2017
Purpose: Over 75% of all solid tumor cancers are characterized by aberrant expression of MUC1. Yet to date, no effective MUC1 targeting therapeutic has succeeded.
Luke T. Deary, Andrew K. Stewart, Jared L. Dietz, Cynthia Carol Bamdad, Benoit J. Smagghe, Victoria L. Kohler   +5 more
core   +1 more source

Binding of GO-203 to endogenous MUC1-C.

, 2015
(A) ZR-75-1 and (B) H1975 cells were left untreated (control), and treated with 5 μM FITC-GO-203 overnight. Lysis was performed in a non-reducing buffer.
James Lee (212552), Pankaj Sharma (58141), Praveen Agarwal (782494), Surender Kharbanda (782495), C. James McKnight (252685), Deepak Raina (782493), Donald Kufe (153971), Ajit Bharti (237911)   +7 more
core   +1 more source